102 related articles for article (PubMed ID: 28356029)
1. Oncogenic Role of SET/I2PP2A for Gynecologic Cancers.
Jiang SW; Xu S; Chen H; Liu J; Duan P
Curr Drug Targets; 2017; 18(10):1152-1157. PubMed ID: 28356029
[TBL] [Abstract][Full Text] [Related]
2. Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).
Jiang SW; Xu S; Chen H; Liu X; Tang Z; Cui Y; Liu J
Clin Chim Acta; 2017 Jan; 464():155-159. PubMed ID: 27836688
[TBL] [Abstract][Full Text] [Related]
3. Zinc Finger and X-Linked Factor (ZFX) Binds to Human SET Transcript 2 Promoter and Transactivates SET Expression.
Xu S; Duan P; Li J; Senkowski T; Guo F; Chen H; Romero A; Cui Y; Liu J; Jiang SW
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775603
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
5. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
6. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
9. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer.
Yuan X; Zhang T; Zheng X; Zhang Y; Feng T; Liu P; Sun Z; Qin S; Liu X; Zhang L; Song J; Liu Y
Oncol Rep; 2017 Sep; 38(3):1733-1741. PubMed ID: 28677734
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated silencing of I2PP2A through RNA interference attenuates trichloroethylene-induced cytotoxicity in human hepatic L-02 cells.
Yang X; Jiang Y; Li J; Hong WX; Wu D; Huang X; Huang H; Zhou L; Yang L; Yuan J; Zhuang Z; Liu J
Toxicol Lett; 2012 Mar; 209(3):232-8. PubMed ID: 22245669
[TBL] [Abstract][Full Text] [Related]
13. SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation.
Almeida LO; Neto MPC; Sousa LO; Tannous MA; Curti C; Leopoldino AM
Oncotarget; 2017 Apr; 8(16):26802-26818. PubMed ID: 28460463
[TBL] [Abstract][Full Text] [Related]
14. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.
Shu G; Zhang L; Jiang S; Cheng Z; Wang G; Huang X; Yang X
Oncotarget; 2016 Jun; 7(26):40285-40296. PubMed ID: 27244888
[TBL] [Abstract][Full Text] [Related]
15. Ceramide in the prostate.
Dent P
Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
[TBL] [Abstract][Full Text] [Related]
16. Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion.
Li J; Yang XF; Ren XH; Meng XJ; Huang HY; Zhao QH; Yuan JH; Hong WX; Xia B; Huang XF; Zhou L; Liu JJ; Zou F
Biochem Biophys Res Commun; 2014 Oct; 453(1):7-12. PubMed ID: 25234598
[TBL] [Abstract][Full Text] [Related]
17. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
18. Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity.
Al-Murrani SW; Woodgett JR; Damuni Z
Biochem J; 1999 Jul; 341 ( Pt 2)(Pt 2):293-8. PubMed ID: 10393085
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
[TBL] [Abstract][Full Text] [Related]
20. SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line.
Sobral LM; Coletta RD; Alberici LC; Curti C; Leopoldino AM
FEBS J; 2017 Sep; 284(17):2774-2785. PubMed ID: 28636114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
